レッドバイオテクノロジーの世界市場 - 現状分析と予測（2022年～2028年）

世界のレッドバイオテクノロジーの市場規模は、予測期間中に約6％の大幅な成長が予測されています。希少疾患の増加、ウイルスの突然変異の発生、政府と民間の組織による生物製剤産業への投資の増加などが、市場成長に寄与する要因となっています。

当レポートでは、世界のレッドバイオテクノロジー市場について調査分析し、市場規模と予測分析、主な動向と機会、企業プロファイルなどの情報を提供しています。

目次

第1章 市場のイントロダクション

第2章 調査手法・前提条件

第3章 市場の要約

第4章 エグゼクティブサマリー

第5章 レッドバイオテクノロジー市場に対するCOVID-19の影響

第6章 レッドバイオテクノロジー市場の収益（2020年～2028年）

第7章 市場の考察：用途別

• バイオ医薬品の生産
• 遺伝子治療
• ファーマコゲノミクス
• 遺伝子検査
• その他

第8章 市場の考察：製品タイプ別

• 遺伝子組換え医薬品
• ヒト用ワクチン
• 血液製剤
• 診断試薬
• 個別化医療
• その他

第9章 市場の考察：地域別

• 北米
  • 米国
  • カナダ
  • その他の北米
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他の地域

第10章 レッドバイオテクノロジーの市場力学

• 市場促進要因
• 市場の課題
• 影響の分析

第11章 レッドバイオテクノロジー市場の機会

第12章 レッドバイオテクノロジー市場の動向

第13章 デマンドサイドとサプライサイドの分析

• デマンドサイド分析
• サプライサイド分析

第14章 バリューチェーン分析

第15章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第16章 企業プロファイル

• Pfizer Inc.
• AstraZeneca PLC
• F. Hoffmann-La Roche Ltd
• Celgene Corporation
• Takeda Pharmaceutical Company Limited
• Biogen Inc.
• Amgen Inc.
• Gilead Sciences Inc.
• Merck & Co. Inc.
• CSL Limited

第17章 免責事項

The global red biotechnology market is expected to grow at a significant rate of around 6% during the forecast period. Biopharmaceuticals are complex medicines made from living cells or organisms, often produced using cutting-edge biotechnological methods. The reliability and safety of biopharmaceutical products along with their ability to treat rare diseases are among the important factors responsible for the market growth of the biopharmaceutical industry. Furthermore, the rising number of orphan diseases, the occurrence of mutation in the viruses, and increasing investments in the biologics industry by government & private organizations are also contributing factors to the market growth of red biotechnology. For instance, in July 2022, vaccine maker Biological E announced its expansion plans for investment of over Rs 1,800 crore.

Pfizer Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Celgene Corporation, Takeda Pharmaceutical Company Limited, Biogen Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co. Inc., and CSL Limited are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst Application, pharmacogenomics category to witness higher CAGR during the forecast period"

Based on the application, the market has been categorized into biopharmaceutical production, gene therapy, pharmacogenomics, genetic testing, and others. The pharmacogenomics category is expected to witness a higher CAGR during the forecast period. The rising number of genetic disorders along with the increasing number of autoimmune disorders and the rising biotechnology industry in developing nations is responsible for the segmental growth of pharmacogenomics.

"Amongst Product Type, human vaccines to hold a significant share in the market in 2020"

Based on the product type, the market has been categorized into gene recombinant drugs, human vaccines, blood products, diagnostics reagents, personalized medicines, and others. Among them, the human vaccines segment is expected to have significant growth in the market during the forecast period. The rising government efforts to increase vaccination along with vaccines provide long-term solutions against the disease is attributed to the growth of the market. For instance, as per the national health mission, Universal Immunization Program (UIP) is one of the largest public health programs targeting close of 2.67 crore newborns and 2.9 crore pregnant women annually.

"North America to hold a dominant share in the market"

For a better understanding of the market adoption of the red biotechnology industry, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. In 2020, North America held a significant share of the global red biotechnology market. This is mainly attributed to the presence of major economies along with the higher R&D investment in the rising biotechnology industry in the region. Furthermore, the launch of various treatment and biopharmaceutical drugs is also an important reason for the considerable growth of the regional growth of the red biotechnology industry. For instance, in June 2021, Jazz Pharmaceuticals plc announced the U.S. Food and Drug Administration (FDA) approval of Rylaze™ for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in pediatric and adult patients who have developed hypersensitivity to E. coli-derived asparaginase.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

The global red biotechnology market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Red Biotechnology Market
• 2.2. Research Methodology of the Red Biotechnology Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE RED BIOTECHNOLOGY MARKET

6 RED BIOTECHNOLOGY MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY APPLICATION

• 7.1. Biopharmaceutical Production
• 7.2. Gene therapy
• 7.3. Pharmacogenomics
• 7.4. Genetic Testing
• 7.5. Others

8 MARKET INSIGHTS BY PRODUCT TYPE

• 8.1. Gene Recombinant Drugs
• 8.2. Human Vaccines
• 8.3. Blood Products
• 8.4. Diagnostics Reagents
• 8.5. Personalized Medicines
• 8.6. Others

9 MARKET INSIGHTS BY REGION

• 9.1. North America
  • 9.1.1. U.S.
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe
  • 9.2.1. Germany
  • 9.2.2. U.K.
  • 9.2.3. France
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia-Pacific
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Rest of Asia-Pacific
• 9.4. Rest of World

10 RED BIOTECHNOLOGY MARKET DYNAMICS

• 10.1. Market Drivers
• 10.2. Market Challenges
• 10.3. Impact Analysis

11 RED BIOTECHNOLOGY MARKET OPPORTUNITIES

12 RED BIOTECHNOLOGY MARKET TRENDS

13 DEMAND AND SUPPLY-SIDE ANALYSIS

• 13.1. Demand Side Analysis
• 13.2. Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 COMPETITIVE SCENARIO

• 15.1. Competitive Landscape
  • 15.1.1. Porters Fiver Forces Analysis

16 COMPANY PROFILED

• 16.1. Pfizer Inc.
• 16.2. AstraZeneca PLC
• 16.3. F. Hoffmann-La Roche Ltd
• 16.4. Celgene Corporation
• 16.5. Takeda Pharmaceutical Company Limited
• 16.6. Biogen Inc.
• 16.7. Amgen Inc.
• 16.8. Gilead Sciences Inc.
• 16.9. Merck & Co. Inc.
• 16.10. CSL Limited

17 DISCLAIMER